Skip to content
value.today
Total raised
$183 M
7 rounds on record
Latest round
$65 M
Apr 2019
First round on record
Jul 2008
Today
Went public
See the company page

Pulmonx is listed today as Pulmonx Corporation: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pulmonx
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2019$65 MNo. 7$50 to $250 million

Pulmonx: Raise no. 7, Apr 2019

Investors in this round

18 investors had bought by the notice of Apr 29, 2019: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series G-1 Preferred Stock; Common Stock issuable upon converison
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Glendon E. French · Executive Officer, Director
  • Lauren G. Cristina · Executive Officer
  • Charles G. Chon · Director
  • Dana G. Mead, Jr · Director
  • Michael E. Matly · Director
  • Oern G. Stuge · Director
  • Rich E. Ferrari · Director
  • Rodney E. Perkins, M.D. · Director
  • Staffan E. Lindstrand · Director
  • Stephen E. Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Glendon E. French, Ceo. Source: SEC Form D, newest notice filed Apr 29, 2019. Read the notice at the SEC.

equitySEC
Jun 2015$50 MNo. 6$50 to $250 million

Pulmonx: Raise no. 6, Jun 2015

Investors in this round

1 investor had bought by the notice of Apr 3, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Glendon E. French · Executive Officer, Director
  • Lauren G. Cristina · Executive Officer
  • Dana G. Mead, Jr · Director
  • Michael E. Matly · Director
  • Oern G. Stuge · Director
  • Rich E. Ferrari · Director
  • Rodney E. Perkins, M.D. · Director
  • Staffan E. Lindstrand · Director
  • Stephen E. Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series F-1 Preferred Stock; Common Stock issuable upon conversion”
  • On the use of proceeds: “Proceeds will be used for general corporate purposes including, but not limited to, executive salaries.”

Signed by Glendon E. French, Ceo. Source: SEC Form D, newest notice filed Apr 3, 2017. Read the notice at the SEC.

equitySEC
Mar 2014$10 MNo. 5$10 to $50 million

Pulmonx: Raise no. 5, Mar 2014

Investors in this round

17 investors had bought by the notice of Apr 1, 2014: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $12 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lauren Cristina · Executive Officer
  • Martin Schneider · Executive Officer
  • Michael Baker · Executive Officer
  • Rodney Perkins, M.D. · Executive Officer, Director
  • Annette Campbell-White · Director
  • Dana Mead · Director
  • Howard Palefsky · Director
  • Rich Ferrari · Director
  • Staffan Lindstrand · Director
  • Steve Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey Leonard, Secretary. Source: SEC Form D, newest notice filed Apr 1, 2014. Read the notice at the SEC.

equitySEC
Jan 2012$10 MNo. 4$10 to $50 million

Pulmonx: Raise no. 4, Jan 2012

Investors in this round

13 investors had bought by the notice of Feb 7, 2012: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Michael Baker · Executive Officer, Director
  • Annette Campbell-White · Director
  • Dana Mead · Director
  • Howard Palefsky · Director
  • Rich Ferrari · Director
  • Rodney Perkins, M.D. · Director
  • Staffan Lindstrand · Director
  • Steve Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey Leonard, Secretary. Source: SEC Form D, newest notice filed Feb 7, 2012. Read the notice at the SEC.

equitySEC
Feb 2010$34 MNo. 3$10 to $50 million

Pulmonx: Raise no. 3, Feb 2010

Investors in this round

18 investors had bought by the notice of Apr 30, 2010: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Michael Baker · Executive Officer, Director
  • Niyazi Beyhan · Executive Officer
  • Annette Campbell-White · Director
  • Dana Mead · Director
  • Howard Palefsky · Director
  • Rich Ferrari · Director
  • Rodney Perkins, M.D. · Director
  • Staffan Lindstrand · Director
  • Steve Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey Leonard, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Apr 30, 2010. Read the notice at the SEC.

equity, optionsSEC
Mar 2009$3 MNo. 2$2 to $10 million

Pulmonx: Raise no. 2, Mar 2009

Investors in this round

2 investors had bought by the notice of Apr 6, 2009: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Ca

People named in the notice

  • Annette Campbell-White · Director
  • Howard Palefsky · Director
  • Rich Ferrari · Director
  • Rodney Perkins, M.D. · Director
  • Steve Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey Leonard, Secretary. Source: SEC Form D, newest notice filed Apr 6, 2009. Read the notice at the SEC.

equitySEC
Jul 2008$12 MNo. 1$10 to $50 million

Pulmonx: Raise no. 1, Jul 2008

Investors in this round

11 investors had bought by the notice of Jan 14, 2010: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Pulmonx as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Michael Baker · Executive Officer
  • Niyazi Beyhan · Executive Officer
  • Annette Campbell-White · Director
  • Howard Palefsky · Director
  • Rich Ferrari · Director
  • Rodney Perkins, M.D. · Director
  • Steve Salmon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Geoffrey Leonard, Secretary. Source: SEC Form D and 3 amendments, newest notice filed Jan 14, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pulmonx chose not to state its revenue in its newest notice of a funding round (Apr 2019).

    SEC Form D · Apr 2019

  • The industry group it chose in its notices: Other.

    SEC Form D · Apr 2019

That is all the official record says: Pulmonx has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pulmonx are on record.

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Pulmonx
InvestorKindAmountRoundRoleSource
Boston Scientific CorpCompanynot statednot statedHeld Series A-1, B-1, C-1, D-1, E-1, F-1 and G-1 preferred (Form 3, 2020)SEC Form 3
Richard M. FerrariPersonnot statednot statedHeld Series G-1 preferred stock, director (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 18 investors.

Largest shareholders today

Institutions holding Pulmonx Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pulmonx
NameRoleNamed in
Glendon E. FrenchExecutive officerApr 2019
Lauren G. CristinaExecutive officerApr 2019
Lauren CristinaExecutive officerApr 2014
Martin SchneiderExecutive officerApr 2014
Michael BakerExecutive officerApr 2014
Rodney Perkins, M.D.Executive officerApr 2014
Niyazi BeyhanExecutive officerApr 2010
Charles G. ChonDirectorApr 2019
Dana G. Mead, JrDirectorApr 2019
Glendon E. FrenchDirectorApr 2019
Michael E. MatlyDirectorApr 2019
Oern G. StugeDirectorApr 2019
Rich E. FerrariDirectorApr 2019
Rodney E. Perkins, M.D.DirectorApr 2019
Staffan E. LindstrandDirectorApr 2019
Stephen E. SalmonDirectorApr 2019
Annette Campbell-WhiteDirectorApr 2014
Dana MeadDirectorApr 2014
Howard PalefskyDirectorApr 2014
Rich FerrariDirectorApr 2014
Rodney Perkins, M.D.DirectorApr 2014
Staffan LindstrandDirectorApr 2014
Steve SalmonDirectorApr 2014
Michael BakerDirectorFeb 2012

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.